The Geneva Foundation 1 article published in JoVE Neuroscience A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors Krishna P. Kota1,6, Veronica Soloveva2,6,7, Laura M. Wanner3,6, Glenn Gomba4,6, Erkan Kiris3,5,6, Rekha G. Panchal6, Christopher D. Kane2,6,7, Sina Bavari6 1Perkin Elmer Inc., 2Henry M. Jackson Foundation, 3The Geneva Foundation, 4ORISE, 5Frederick National Laboratory for Cancer Research, 6Division of Molecular and Translational Sciences, US Army Medical Research Institute of Infectious Diseases, 7DoD Biotechnology High Performance Computing Software Applications Institute (BHSAI), Telemedicine and Advanced Technology Research Center (TATRC), US Army Medical Research and Materiel Command (USAMRMC) Botulinum neurotoxin is one of the most potent toxins among Category-A biothreat agents, yet a post-exposure therapeutic is not available. The high content imaging approach is a powerful methodology for identifying novel inhibitors as it enables multiparameter screening using biologically relevant motor neurons, the primary target of this toxin.
